Adimab initiates new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences

Adimab, Inc., a technology leader in the discovery of fully human antibodies, today announced the initiation of three new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences. Over the past 18 months Adimab has established collaborations with several leading Pharmaceutical companies including: Merck, Roche, Novartis, Pfizer, and now Eli Lilly, Genentech, and Human Genome Sciences.

“Adimab's platform is unique in comparison to any other antibody discovery technology. By incorporating target biology into the selection process we are able to generate very high quality leads in a short timeframe”

"As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab's deal flow speaks for itself," said Tillman Gerngross, Adimab's CEO and co-founder. "In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology."

In addition to the three new collaborations, Adimab announced the achievement of a technical milestone in its ongoing collaboration with Novartis, which was initiated in June of 2010. Adimab also announced that Merck has exercised its option to start an additional project around a 2^nd target.

"Adimab's platform is unique in comparison to any other antibody discovery technology. By incorporating target biology into the selection process we are able to generate very high quality leads in a short timeframe," said Guy Van Meter, Adimab's Senior Director of Business Development. "The most sophisticated buyers in the industry understand the impact Adimab could have on their pipelines. Since launching the platform in June of 2009, we have closed a total of 15 funded discovery programs, including 10 new programs in 2010."